Does Obamacare cover Wegovy? In almost all cases, no — Affordable Care Act Marketplace plans do not cover Wegovy when it’s prescribed for weight loss. As of 2026, only 26 of roughly 300 carriers on the ACA exchanges include any GLP-1 drug on their formularies for obesity treatment, and the number of enrollees with that coverage has been shrinking rather than growing.1Becker’s Payer Issues. GLP-1 Coverage Under ACA Plans Continues to Decline If your plan is one of the few that does cover it, expect strict medical criteria. If it doesn’t, the manufacturer and federal programs now offer self-pay prices well below the drug’s roughly $1,350 list price.2GoodRx. Wegovy for Weight Loss Cost and Coverage
Why ACA Plans Usually Skip Weight-Loss Drugs
Weight-loss medications are not classified as essential health benefits under the ACA, so insurers selling Marketplace plans have no federal obligation to cover them. A 2024 Kaiser Family Foundation analysis found that only about 1% of prescription drug formularies on HealthCare.gov included Wegovy for weight loss.3KFF. Costly GLP-1 Drugs Are Rarely Covered for Weight Loss by Marketplace Plans Counting state-based exchanges, fewer than 5% of Marketplace enrollees were in a plan that covered it.4Robert Wood Johnson Foundation. Marketplace Pulse: Coverage of Obesity Therapies in State-Regulated Markets
By 2026, the picture had gotten worse. Several major insurers dropped weight-loss drug coverage on January 1, 2026, citing unsustainable costs, and the number of enrollees with access fell from 3.6 million in 2024 to roughly 2.8 million.1Becker’s Payer Issues. GLP-1 Coverage Under ACA Plans Continues to Decline
The core problem is cost. At list prices above $1,000 per month, broad coverage of these drugs for the roughly 100 million American adults with obesity would be extraordinarily expensive. The U.S. Preventive Services Task Force, whose recommendations trigger mandatory no-cost coverage under the ACA, recommends behavioral interventions for adults with obesity but has not extended that recommendation to medication. Its review of drug trials noted “highly selective inclusion criteria” and high dropout rates, making it “unclear how well patients tolerate these medications.”5USPSTF. Obesity in Adults: Interventions Until the Task Force changes course or Congress intervenes, there is no federal mechanism forcing ACA plans to cover Wegovy.
Which States and Carriers Do Cover It
Coverage, where it exists, is concentrated in nine states: California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware, and Georgia.1Becker’s Payer Issues. GLP-1 Coverage Under ACA Plans Continues to Decline In California and North Dakota, every carrier on the exchange offers it. In the other seven states, coverage is usually limited to one or two insurers.
North Dakota is the only state that has formally mandated this coverage. Its updated Essential Health Benefits benchmark, approved by federal regulators in August 2023 and effective January 1, 2025, covers semaglutide (the active ingredient in Wegovy) and tirzepatide for the prevention of diabetes and the treatment of insulin resistance, metabolic syndrome, or morbid obesity.6North Dakota Insurance Department. ND INS EHB Changes Blue Cross Blue Shield of North Dakota, the dominant insurer in the state, began offering the coverage on that date.7Becker’s Payer Issues. The First State to Cover Ozempic Under the ACA Similar legislation in California, Maine, and New Hampshire has either failed or is still pending.
What the Plans That Cover Wegovy Require
If your plan is one of the few that includes Wegovy, access is tightly controlled. Every carrier that covers the drug requires prior authorization, and most impose additional conditions.1Becker’s Payer Issues. GLP-1 Coverage Under ACA Plans Continues to Decline
- A BMI threshold. All but four of the 26 covering carriers restrict coverage to patients with a BMI of 40 or higher, which corresponds to severe obesity.
- Documented prior weight-loss attempts. Carriers typically require proof of three to nine months of unsuccessful diet and exercise before authorizing the drug.
- Ongoing documentation. Reauthorization every 6 to 12 months is common, with proof of continued weight loss or weight maintenance.
UnitedHealthcare’s policy for its North Dakota fully insured plans requires an initial BMI of at least 40, participation in lifestyle modification, and documented weight loss of at least 5% from baseline to continue therapy.8UnitedHealthcare. Prior Authorization/Notification – Weight Loss CVS Caremark is slightly less restrictive on BMI (30 or above, or 27 with a comorbidity) but adds a mandatory six-month participation in a comprehensive weight management program before coverage begins.9CVS Caremark. Rx Criteria – Wegovy
Coverage Is Different if You Have Diabetes or Heart Disease
The ACA coverage story changes substantially when the same active ingredient is prescribed for a different condition. Ozempic, which is semaglutide prescribed for type 2 diabetes, was covered by 82% of Marketplace formularies as of 2024.3KFF. Costly GLP-1 Drugs Are Rarely Covered for Weight Loss by Marketplace Plans If you have type 2 diabetes, your plan likely covers a semaglutide product under its diabetes benefits even if it excludes Wegovy for weight loss.
The FDA also approved Wegovy in March 2024 for a second use: reducing the risk of heart attack and stroke in patients with established cardiovascular disease who are overweight or obese.10NPR. Wegovy Medicare Part D Weight Loss Drugs That approval opened a path for some patients to get the drug covered for cardiovascular risk reduction rather than weight loss alone. Whether your Marketplace plan will cover it on that basis depends on the formulary and the specifics of your diagnosis.
Paying Out of Pocket
Several routes now exist for people whose insurance will not cover Wegovy.
Novo Nordisk, the manufacturer, offers direct self-pay pricing through its NovoCare program. The Wegovy pill is $149 per month for the 1.5 mg and 4 mg doses. The injectable pen is $199 per month for new patients on starter doses and $349 per month for other injectable doses.11Wegovy. What to Pay for Wegovy
If you have commercial insurance that already covers Wegovy, the manufacturer’s savings card can bring your copay down to as little as $25 per month. ACA Marketplace enrollees and Federal Employee Health Benefits enrollees are explicitly eligible for the savings card. People on Medicare, Medicaid, or Tricare are not.12NovoCare. Wegovy Savings Offer
The TrumpRx portal (trumprx.gov), launched in February 2026, lists Wegovy pills at $149 per month and Wegovy pens at $199 per month.13TrumpRx. TrumpRx The site itself doesn’t sell drugs; it connects users to manufacturer programs or pharmacy coupons. One caveat: purchases through TrumpRx do not count toward your insurance deductible or out-of-pocket maximum.14STAT News. TrumpRx: What to Know About Drug Prices
The FDA approved an oral Wegovy tablet on December 22, 2025.15Novo Nordisk. Wegovy Pill FDA Approval The maintenance dose is 25 mg once daily, compared with 2.4 mg once weekly for the injection, and patients titrate up over roughly 90 days.16FDA. Wegovy Prescribing Information The pill’s self-pay price is lower than the injectable, and publicly available information does not indicate that insurers treat the two forms differently for coverage purposes.17NovoCare. Wegovy Check Coverage The same prior authorization rules generally apply.
If You’re on Medicare or Medicaid Instead
Medicare and Medicaid rules are separate from ACA Marketplace coverage, and people sometimes conflate the three programs.
Federal law has long prohibited Medicare from paying for drugs used solely for weight loss, and that statutory bar is still in place. The Biden administration proposed in November 2024 to reinterpret the exclusion to allow coverage for obesity treatment, but the Trump administration declined to finalize that proposal on April 4, 2025.18Georgetown University. Policy Options to Cover Anti-Obesity Drugs Instead, a demonstration project called the Medicare GLP-1 Bridge runs from July 1, 2026, through December 31, 2027, offering Wegovy and Zepbound to eligible Part D beneficiaries at a $50 monthly copay, with eligibility tied to BMI and specific clinical conditions.19CMS. Medicare GLP-1 Bridge
For Medicaid, federal law lets states exclude weight-loss drugs, and most do. As of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for weight-loss treatment, and California, New Hampshire, Pennsylvania, and South Carolina all eliminated that coverage between October 2025 and January 2026.20KFF. Medicaid Coverage of and Spending on GLP-1s State Medicaid programs are required to cover GLP-1 drugs for other FDA-approved uses, including type 2 diabetes, cardiovascular risk reduction, and obstructive sleep apnea.